(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) demonstrated durable clinical, endoscopic, and histologic benefit in a large real-world cohort of patients with ulcerative colitis (UC), with many maintaining remission over time and others…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






